Axsome Therapeutic's drug, Auvelity was approved for depression in 2022, and completed it's first full year of commercialization in 2023. The chart below is quarterly prescription data derived from a couple different sources, Bloomberg and IQVIA. The numbers are climbing from quarter to quarter, which is positive. The third quarter of 2025 numbers have not been released yet, so a rough estimate (2221,000) has been created based on data tracking. See chart below of prescription data. Axsome reports third quarter results on November 3rd.
No comments:
Post a Comment